For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Vir Biotechnology Inc (NASDAQ: VIR) closed at $7.12 up 2.45% from its previous closing price of $6.95. In other words, the price has increased by $2.45 from its previous closing price. On the day, 0.89 million shares were traded. VIR stock price reached its highest trading level at $7.27 during the session, while it also had its lowest trading level at $6.88.
Ratios:
For a deeper understanding of Vir Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.94 and its Current Ratio is at 8.94. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’24 when de Verneuil Vanina sold 4,397 shares for $10.11 per share. The transaction valued at 44,454 led to the insider holds 56,973 shares of the business.
VANINA DE VERNEUIL bought 4,397 shares of VIR for $42,387 on Nov 06 ’24. On Nov 05 ’24, another insider, de Verneuil Vanina, who serves as the EVP and General Counsel of the company, sold 2,347 shares for $9.47 each. As a result, the insider received 22,225 and left with 61,370 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 980566400 and an Enterprise Value of 178906256. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.78 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 2.276 whereas that against EBITDA is -0.335.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $13.09, while it has fallen to a 52-week low of $6.56. The 50-Day Moving Average of the stock is -9.95%, while the 200-Day Moving Average is calculated to be -22.20%.
Shares Statistics:
For the past three months, VIR has traded an average of 1.01M shares per day and 1360940 over the past ten days. A total of 134.78M shares are outstanding, with a floating share count of 87.31M. Insiders hold about 36.61% of the company’s shares, while institutions hold 49.44% stake in the company. Shares short for VIR as of 1730332800 were 5721806 with a Short Ratio of 5.67, compared to 1727654400 on 5726219. Therefore, it implies a Short% of Shares Outstanding of 5721806 and a Short% of Float of 6.74.
